Australia's Immuron jumps on record monthly sales of Travelan in August
** Shares of Immuron IMC.AX up 23% at A$0.091 - their
highest level since Aug 9
** Biopharmaceutical co says posted record monthly sales of
its digestive health immune supplement Travelan
** Co sees sustained demand for replenishment of Travelan
** Stock set for best day since Aug 9, if gains hold
** Stock down 14% this year, as of last close
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com;))
Recent news on Immuron
See all newsBrief: Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
Australia's Immuron hits near 1.5-month high on distribution deal in US
Brief: Immuron Executes Exclusive Distribution Agreement For Proibs In The United States
Brief: Immuron Reports FY26 Preliminary Results
Brief: Immuron Posts FY Revenue From Ordinary Activities Of A$7.71 Million